Follow Us

       


"Like" us on Facebook

Clinical Trials

Disease or Condition
Cancer - Melanoma
Title
BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Description
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically-Resected Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence (GO27826)
IRB Number
NCT01667419
Inclusion/Notes

Please contact the research department for full eligibility details.

For additional information, please click here: http://clinicaltrials.gov/ct2/show/NCT01667419

Status
Open to Enrollment
Principal Investigator
Frederic C. Kass, MD
Contact Email
research@ccsb.org
Phone
(805) 898-2117

This is the fat footer - edit page 906 to add content.